Showing 9721-9730 of 21392 results for "".
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
https://reachmd.com/programs/spotlight-subcutaneous-cancer-immunotherapies/nanrilkefusp-alfa-a-promising-subcutaneous-il-15r-superagonist/32991/Read about the mechanisms, safety, and efficacy of nanrilkefusp alfa, an IL-15 receptor βγ superagonist designed to stimulate NK and CD8+ T cells.Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
https://reachmd.com/programs/project-oncology/akt-inhibitor-ae-hr-positive-her2-negative-advanced-bc/54763/In HR+/HER2- advanced breast cancer, effective management of AKT inhibitor-associated adverse events (AEs) begins well before treatment initiation. To learn more about how proactive planning and patient-centered strategies can help reduce the risks of hyperglycemia, rash, and diarrhea, Dr. Charles TUnraveling PMR Pathophysiology: The Central Role of IL-6
https://reachmd.com/programs/medical-industry-feature/pmr-pathophysiology-central-role-il-6/56659/Polymyalgia rheumatica (PMR) involves an aberrant activation of both the innate and adaptive branches of the immune system. This immune response leads to the secretion of several pro-inflammatory cytokines, including TNFα, IL-1, IL-10, IL-17, IFNγ, and IL-6.1 IL-6 is believed to be a major driver ofHow the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
https://reachmd.com/programs/project-oncology/2025-imwg-guidelines-sequencing-rr-myeloma/39922/This is a non-certified educational series produced and controlled by ReachMD. The latest International Myeloma Working Group (IMWG) guidelines emphasize immune function, relapse timing, and therapeutic intent to guide the sequencing of T-cell-redirecting therapies in relapsed/refractory (R/R) multiUnlocking Early Detection of IgA Nephropathy: The Critical Role of Timely Diagnosis
https://reachmd.com/programs/frontlines-iga-nephropathy/unlocking-early-detection-of-iga-nephropathy-the-critical-role-of-timely-diagnosis/26945/Here’s how early identification of IgA nephropathy can improve patient outcomes.How Delayed Colorectal Cancer Screening Impacts Quality of Life
https://reachmd.com/programs/clinicians-roundtable/delayed-colorectal-cancer-screening-quality-of-life/56448/Delayed colorectal cancer screening can significantly impact not only clinical outcomes, but also patients’ long-term quality of life. Tune in to hear Dr. Christopher Cann share his insights on these lasting consequences, including the need for more extensive surgery and systemic therapies, the burdRethinking Who Qualifies for Advanced IBD Therapy
https://reachmd.com/programs/gi-insights/rethinking-who-qualifies-for-advanced-ibd-therapy/70073/Regulatory approvals for advanced inflammatory bowel disease (IBD) therapies still hinge on disease severity, but Dr. Gil Melmed argues that framework no longer reflects who actually benefits from treatment. Tune in to hear him discuss the case for flipping the traditional approach, from asking whetHow Myeloid Mutations in ALL Inform Treatment Decisions
https://reachmd.com/programs/project-oncology/myeloid-mutations-all-treatment-decisions/54356/Identifying myeloid-associated and TP53 mutations in adults with acute lymphoblastic leukemia (ALL) may have important implications for treatment planning. Join Dr. Caner Saygin as he discusses how comprehensive genomic assessment can help inform the use of novel immune-based therapies and chemotherGut Microbiome Mechanisms Shaping Immune Responses to Allergens
https://reachmd.com/programs/clinicians-roundtable/gut-microbiome-immune-response-allergens/54220/Emerging research is redefining the role of the gut microbiome in food allergy and immune tolerance. Here to share some of the most groundbreaking findings is Dr. Mustafa Ozcam. He discusses how gut microbes metabolize allergenic proteins, shape immune development, and serve as potential biomarkersPotential Impact of Aryl Hydrocarbon Activation on Pigment
https://reachmd.com/programs/practical-dermatology/potential-impact-of-aryl-hydrocarbon-activation-on-pigment/70710/In the sixth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, speculate about normalization of pigment as a potential benefit of aryl hydrocarbon receptor agonism.